Prospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Figure 1
Figure 1 Representative case of a 69-year-old man with unresectable hepatocellular carcinoma treated with lenvatinib (12 mg/d). A: Contrast-enhanced ultrasound (CEUS) imaging in the arterial phase at Day 0 and time-intensity curve (TIC) analysis. The region of interest was established within the demarcation margins of the target tumor. B: CEUS imaging at Day 7 and TIC analysis. The slope became gentle, and indicated a delay in TTP and a decrease in the area under the curve. C: Computed tomography (CT) image at Day 0. D: CT image at 8 wk. Therapeutic response was evaluated as partial response using the modified Response Evaluation Criteria in Solid Tumors. TTP: Time to peak; AUC: Area under the curve.
Figure 2
Figure 2 The rates of change of time-intensity curve parameters in responders and non-responders. A: Slope, B: time to peak, C: area under the curve. The rates of change of all time-intensity curve parameters were significantly different in responders and non-responders. TTP: Time to peak; AUC: Area under the curve.